Latest News and Press Releases

AMRYT REPORTS RECORD Q3 2020 RESULTS 19% YoY revenue growth in the quarter to $49.3M Raising full year revenue guidance to $180M - $182M Both metreleptin and lomitapide driving revenue...

AMRYT ANNOUNCES POSITIVE RESULTS FROM PHASE 3 TRIAL OF FILSUVEZ® IN EPIDERMOLYSIS BULLOSA LATE-BREAKING ORAL PRESENTATION AT THE 29TH EADV (VIRTUAL) CONGRESS ON OCTOBER 31 Virtual Analyst &...

AMRYT PHARMA PLC (“Amryt” or the “Company”) AMRYT AND SWIXX SIGN DISTRIBUTION DEAL FOR LOJUXTA® ACROSS 17 JURISDICTIONS IN CENTRAL AND EASTERN EUROPE (“CEE”)  DUBLIN, Ireland, and Boston MA,...

AMRYT PHARMA PLC (“Amryt” or the “Company”) AMRYT TO ANNOUNCE Q3 RESULTS ON NOVEMBER 5, 2020 DUBLIN, Ireland, and Boston MA, October 14 2020,  Amryt (Nasdaq: AMYT, AIM: AMYT), a global,...

TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i 1a. Identity of the...

AMRYT PHARMA PLC (“Amryt” or the “Company”) VIRTUAL ANALYST AND INVESTOR EVENT - TUESDAY NOVEMBER 3, 2020 - AMRYT TO PRESENT FULL DATA FROM EASE TRIAL AND LAUNCH PLANS FOR FILSUVEZ® AS A POTENTIAL...

AMRYT PHARMA PLC (“Amryt” or the “Company”) AMRYT TO PRESENT EASE TRIAL DATA BY LATE-BREAKING PRESENTATION AT EADV ON OCTOBER 31, 2020 DUBLIN, Ireland, and Boston MA, October 8 2020,  Amryt...

AMRYT PHARMA PLC (“Amryt” or the “Company”) Exercise of Options and Total Voting Rights DUBLIN, Ireland, and Boston MA, October 1 2020, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage...

TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i 1a. Identity of the...

   AMRYT PHARMA PLC (“Amryt” or the “Company”) AMRYT SUPPORTS GLOBAL FH AWARENESS DAY – SEPTEMBER 24, 2020 DUBLIN, Ireland, and Boston MA, September 23 2020, Amryt (Nasdaq: AMYT, AIM: AMYT), a...